“Global Respiratory Inhalers market set to grow to $41bn by 2025” says new Visiongain report

28 January 2020
Pharma

Visiongain has launched a new pharma report The Global Respiratory Inhalers Market : Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.

Respiratory inhalers are used to relieve the symptoms of asthma and COPD and prevent exacerbations, which can lead to expensive hospital stays for patients and increase the risk of mortality. The market is maturing with the launch of generic products expected during the forecast period. The launch of advanced products such as triple combination therapy and focus on development of e-devices are expected to drive the market growth.

Chekeh Mboge, the lead analyst of the report commented "Emerging countries will experience accelerated growth in the respiratory inhaler market, due to higher standards of living, rising life expectancy and an increase in urbanization. This demand alone will not mitigate falling revenues, and with generics becoming increasingly available due to past and upcoming patent expiry’s, traditional pharma companies are focusing on developing newer inhaler technology. These devices, which track patient usage and share with relevant HCPs, will tackle the huge unmet needs of patients: namely, lack of adherence and improper inhaler techniques. Digital inhalers will lead the way towards a patient pathway characterized by personalization and precision medicine. In addition to providing better health outcomes, these new digital inhalers will act as a high barrier to entry ceiling, to counter generic competition and will significantly drive growth in the market."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim, Chiesi, Farmaceutici S.p.A., GlaxoSmithKline (GSK), Merck & Co., Novartis, Teva and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

Read

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

Read

Visiongain Publishes Respiratory Drug Delivery Technologies Market Report 2022-2032

The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.

15 June 2022

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

14 June 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever